Evidence map›Paper›PMID 31475008›Full record

ArticleFrontiers in immunology2019

Tumor Necrosis Factor-Alpha Antagonist Interferes With the Formation of Granulomatous Multinucleated Giant Cells: New Insights Into

Soraya Mezouar, Issa Diarra, Jean Roudier, Benoit Desnues, Jean-Louis Mege

Abstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. A granulin-positive macrophage subtype in mycobacterial granulomas alleviates tissue damage by limiting excessive inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Review
  6. Review
  7. Expression of a uniqueFrontiers in microbiology · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Antibodies as clinical tools for tuberculosis.Frontiers in immunology · 2023
    Review
  12. Article
  13. Review
  14. Phenotypic adaptation ofFrontiers in cellular and infection microbiology · 2022
    Review
  15. Article
  16. Review
  17. Tuberculosis: The success tale of less explored dormantFrontiers in cellular and infection microbiology · 2022
    Review
  18. Distinguishing Blau Syndrome from Systemic Sarcoidosis.Current allergy and asthma reports · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Soraya MezouarAix-Marseille Université, IRD, APHM, MEPHI, Marseille, France.
Issa DiarraAix-Marseille Université, IRD, APHM, MEPHI, Marseille, France.
Jean RoudierDepartment of Rheumatology, Institut du Mouvement et de l'appareil Locomoteur, APHM, Marseille, France.
Benoit DesnuesAix-Marseille Université, IRD, APHM, MEPHI, Marseille, France.
Jean-Louis MegeAix-Marseille Université, IRD, APHM, MEPHI, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than half of tuberculosis cases in the world are due to resuscitation of dormant

Indexed as

AdalimumabAnti-Inflammatory AgentsApoptosisCells, CulturedEtanerceptGiant CellsGranulomaHumansInterleukin-10Macrophage ActivationMacrophagesMycobacterium tuberculosisTuberculosisTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAdalimumabAnti-Inflammatory AgentsEtanerceptInterleukin-10Tumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitorsetanerceptgranulomainterleukin-10interleukine-17multinucleated giant cellsMycobacterium tuberculosistumor necrosis factor

Identifiers

PMID31475008
PMCPMC6702871

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.